血清壳多糖酶-3样蛋白1在肝纤维化发展作用中的研究进展
Research Progress of Serum Chitosanase-3-Like Protein 1 in the Development of Hepatic Fibrosis
DOI: 10.12677/ACM.2022.127898, PDF,    科研立项经费支持
作者: 卢炎娜：青海大学研究生院，青海 西宁；郜 茜, 王学红：青海大学附属医院消化内科，青海 西宁
关键词: 肝纤维化；血清壳多糖酶-3样蛋白1 (CHI3L1)；肝巨噬细胞；肝星状细胞；造血干细胞；Liver Fibrosis； Serum Chitosanase-3-Like Protein 1 (CHI3L1)； Hepatic Macrophage； Hepatic Stellate Cell； Hemopoietic Stem Cell
摘要: 肝纤维化是肝脏对自身慢性损伤的一种病理性修复反应，是各种慢性肝脏疾病向肝硬化疾病转变过程中的关键步骤。血清壳多糖酶-3样蛋白1 (CHI3L1)是一种新兴的肝纤维化无创血清生物标志物。本文就血清壳多糖酶-3样蛋白1 (CHI3L1)及其在肝纤维化发生发展作用途径中的研究进展做一系统的简要总结，旨在为早期肝纤维化及肝硬化临床诊断及辅助治疗技术提供参考。
Abstract: Hepatic fibrosis is a pathological repair response of the liver to its own chronic injury, and is a key step in the transformation from various chronic liver diseases to cirrhosis. Serum chitosanase-3- like protein 1 (CHI3L1) is a new non-invasive serum biomarker for liver fibrosis. In this paper, the research progress of serum chitosanase-3-like protein 1 (CHI3L1) and its role in the occurrence and development of liver fibrosis is systematically summarized, aiming to provide reference for clinical diagnosis and adjuvant therapy of early liver fibrosis and cirrhosis.
文章引用：卢炎娜, 郜茜, 王学红. 血清壳多糖酶-3样蛋白1在肝纤维化发展作用中的研究进展[J]. 临床医学进展, 2022, 12(7): 6222-6227. https://doi.org/10.12677/ACM.2022.127898

参考文献

[1] 黄丽玲, 吴春城, 梁惠卿, 邱洋佳, 唐金模. 血清标志物壳多糖酶3样蛋白1评价肝纤维化的研究[J]. 医学信息, 2021, 34(10): 32-35.
[2] Zhao, T., Su, Z., Li, Y., Zhang, X. and You, Q. (2020) Chitinase-3 Like-Protein-1 Function and Its Role in Diseases. Signal Transduction and Targeted Therapy, 5, Article No. 201. [Google Scholar] [CrossRef] [PubMed]
[3] 侯永强, 王新征. 血清YKL-40蛋白水平与肝硬化患者肝功能、肝纤维化的相关性及作用机制[J]. 中西医结合肝病杂志, 2019, 29(5): 427-429.
[4] 谭坤, 杨铭. YKL-40在消化系统疾病中作用的研究进展[J]. 现代临床医学, 2012, 38(1): 3-6.
[5] Lee, C.G., Da Silva, C.A., Dela Cruz, C.S., Ahangari, F., Ma, B., Kang, M.J., et al. (2011) Role of Chitin and Chitinase/Chitinase-Like Proteins in Inflammation, Tissue Remodeling, and Injury. Annual Review of Physiology, 73, 479-501. [Google Scholar] [CrossRef] [PubMed]
[6] Wang, S., Hu, M., Qian, Y., Jiang, Z., Shen, L., Fu, L., et al. (2020) CHI3L1 in the Pathophysiology and Diagnosis of Liver Diseases. Biomedicine & Pharmacotherapy, 131, Article ID: 110680. [Google Scholar] [CrossRef] [PubMed]
[7] Johansen, J.S., Olee, T., Price, P.A., Hashimoto, S., Ochs, R.L. and Lotz, M. (2001) Regulation of YKL-40 Production by Human Articular Chondrocytes. Arthritis and Rheumatism, 44, 826-837. [Google Scholar] [CrossRef] 
[8] De Ceuninck, F., Pas-toureau, P., Bouet, F., Bonnet, J. and Vanhoutte, P.M. (1998) Purification of Guinea Pig YKL40 and Modulation of Its Secretion by Cultured Articular Chondrocytes. Journal of cellular biochemistry, 69, 414-424. [Google Scholar] [CrossRef] 
[9] Kzhyshkowska, J., Mamidi, S., Gratchev, A., Kremmer, E., Schmuttermaier, C., Krusell, L., Haus, G., Utikal, J., Schledzewski, K., Scholtze, J. and Goerdt, S. (2006) Novel Stabilin-1 Interacting Chitinase-Like Protein (SI-CLP) Is Up-Regulated in Alternatively Activated Macrophages and Secreted via Lysosomal Pathway. Blood, 107, 3221-3228. [Google Scholar] [CrossRef] [PubMed]
[10] 陶山, 李倩, 陈阳, 范妤, 郭东艳, 翟秉涛, 史晓燕, 段丽芳. 肝巨噬细胞与肝星状细胞交互作用对肝纤维化发生与逆转的影响[J]. 生命科学, 2021, 33(3): 363-373.
[11] 姜娜, 平键, 徐列明, 肝星状细胞的活化机制——探寻肝纤维化新的诊断指标和治疗靶点[J]. 临床肝胆病杂志, 2019, 35(3): 640-643.
[12] 秦利静, 张露, 侯鹏, 钟秀宏. 肝纤维化发病机制的研究进展[J]. 吉林医药学院学报, 2021, 42(5): 369-371.
[13] Johansen, J.S., Christoffersen, P., Møller, S., Price, P.A., Henriksen, J.H., Garbarsch, C., et al. (2000) Serum YKL-40 Is Increased in Patients with Hepatic Fibrosis. Journal of Hepatology, 32, 911-920. [Google Scholar] [CrossRef] 
[14] 秦雨萌, 陈胜华. 肝纤维化进程中细胞外基质对肝星状细胞的作用及机制研究进展[J]. 实用肝脏病杂志, 2017, 20(3): 381-384.
[15] Iwata, T., Kuwajima, M., Sukeno, A., Ishimaru, N., Hayashi, Y., Wabitsch, M., Mizusawa, N., Itakura, M. and Yoshimoto, K. (2009) YKL-40 Secreted from Adipose Tissue Inhibits Degradation of Type I Collagen. Biochemical and Biophysical Research Communications, 388, 511-516. [Google Scholar] [CrossRef] [PubMed]
[16] 李文川, 蔡雪红, 陈巍, 邱英桓, 段小辉, 杨尽晖. CHI3L1在肝切除术后参与肝脏血管再生的研究进展[J]. 中南医学科学杂志, 2021, 49(3): 363-367.
[17] Kumagai, E., Mano, Y., Yoshio, S., Shoji, H., Sugiyama, M., Korenaga, M., et al. (2016) Serum YKL-40 as a Marker of Liver Fi-brosis in Patients with Non-Alcoholic Fatty Liver Disease. Scientific Reports, 6, Article No. 35282. [Google Scholar] [CrossRef] [PubMed]
[18] Pizano-Martínez, O., Yaez-Sánchez, I., Alatorre-Carranza, P., Miran-da-Díaz, A., Ortiz-Lazareno, P.C., García-Iglesias, T., Daneri-Navarro, A., Vázquez-Del Mercado, M., Fafutis-Morris, M. and Delgado-Rizo, V. (2011) YKL40 Expression in CD14+ Liver Cells in Acute and Chronic Injury. World Journal of Gastroenterology, 17, 3830-3835. [Google Scholar] [CrossRef] [PubMed]
[19] Dong, X., Liu, J., Xu, Y. and Cao, H. (2019) Role of Macrophages in Experimental Liver Injury and Repair in Mice. Experimental and Therapeutic Medicine, 17, 3835-3847. [Google Scholar] [CrossRef] [PubMed]
[20] Koyama, Y. and Brenner, D.A. (2017) Liver Inflammation and Fibro-sis. The Journal of Clinical Investigation, 127, 55-64. [Google Scholar] [CrossRef] 
[21] 李灵杰, 许迎迎, 高炳宏. 肌肉因子新成员: CHI3L1/YKL-40[J]. 生命的化学, 2021, 41(9): 1995-2000.
[22] Higashiyama, M., Tomita, K., Sugihara, N., Nakashima, H., Furuhashi, H., Nishikawa, M., et al. (2019) Chitinase 3-Like 1 Deficiency Ameliorates Liver Fibrosis by Promoting Hepatic Macrophage Apoptosis. Hepatology Research, 49, 1316-1328. [Google Scholar] [CrossRef] [PubMed]
[23] Nishimura, N., De Battista, D. and McGivern, D.R., Engle, R.E., Tice, A., Fares-Gusmao, R., et al. (2021) Chitinase 3-Like 1 Is a Profibrogenic Factor Overexpressed in the Aging Liver and in Patients with Liver Cirrhosis. Proceedings of the National Academy of Sciences of the United States of America, 118, Ar-ticle ID: e2019633118. [Google Scholar] [CrossRef] [PubMed]
[24] Friedman, S.L. (2008) Mechanisms of Hepatic Fibrogenesis. Gas-troenterology, 134, 1655-1669. [Google Scholar] [CrossRef] [PubMed]
[25] Ignat, S.-R., Dinescu, S., Hermenean, A., Costache, M. and Weiskirchen, R. (2020) Cellular Interplay as a Consequence of Inflammatory Signals Leading to Liver Fibrosis Devel-opment. Cells, 9, Article No. 461. [Google Scholar] [CrossRef] [PubMed]
[26] Tsuchida, T. and Friedman, S.L. (2017) Mechanisms of Hepatic Stellate Cell Activation. Nature Reviews. Gastroenterology & Hepatology, 14, 397-411. [Google Scholar] [CrossRef] [PubMed]
[27] Kisseleva, T. (2017) The Origin of Fibrogenic Myofibroblasts in Fi-brotic Liver. Hepatology, 65, 1039-1043. [Google Scholar] [CrossRef] [PubMed]
[28] Recklies, A.D., White, C. and Ling, H. (2002) The Chitinase 3-Like Protein Human Cartilage Glycoprotein 39 (HC- gp39) Stimulates Proliferation of Human Connective-Tissue Cells and Activates Both Extracellular Signal-Regulated Kinase- and Protein Kinase B-Mediated Signalling Pathways. Biochemical Journal, 365, 119-126. [Google Scholar] [CrossRef] [PubMed]
[29] Lee, Y.A., Wallace, M.C. and Friedman, S.L. (2015) Pathobiology of Liver Fibrosis: A Translational Success Story. Gut, 64, 830-841. [Google Scholar] [CrossRef] [PubMed]
[30] Puche, J.E, Saiman, Y. and Friedman, S.L. (2013) Hepatic Stellate Cells and Liver Fibrosis. In: Terjung, R., Ed., Comprehensive Physiology, Vol. 3, Wiley, Hoboken, 1473-1492. [Google Scholar] [CrossRef] [PubMed]
[31] Oslobanu, A. and Florian, St.I. (2015) Is YKL-40 (CHI3-L1) a New Possible Biomarker Prognosticator in High Grade Glioma? Romanian Neurosurgery, 29, 247-253.

为你推荐